+

US20060024329A1 - Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. - Google Patents

Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. Download PDF

Info

Publication number
US20060024329A1
US20060024329A1 US10/935,494 US93549404A US2006024329A1 US 20060024329 A1 US20060024329 A1 US 20060024329A1 US 93549404 A US93549404 A US 93549404A US 2006024329 A1 US2006024329 A1 US 2006024329A1
Authority
US
United States
Prior art keywords
nucleotide sequence
heterologous nucleotide
recombinant chv
expresses
insertion site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/935,494
Inventor
Jean-Christophe Audonnet
Philippe Baudu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/935,494 priority Critical patent/US20060024329A1/en
Publication of US20060024329A1 publication Critical patent/US20060024329A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • C07K14/015Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18411Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20111Lyssavirus, e.g. rabies virus
    • C12N2760/20122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to vaccines, preferably for dogs, produced from recombinant canine herpesviruses, and to the methods for obtaining and preparing these recombinant viruses.
  • the present invention relates more especially to recombinant canine herpesviruses comprising an expression cassette for one or more foreign gene(s).
  • Canine herpesvirosis is caused by the canine herpesvirus (CHV).
  • CHV canine herpesvirus
  • the canine herpesvirus (CHV) is classified in the Alphaherpesvirinae family. This herpesvirus is a major pathogen for neonatal puppies.
  • Canine herpesvirosis manifests itself chiefly in a haemorrhagic disease in puppies, and in a benign disease of the upper respiratory apparatus in adult dogs. There are at present no vaccines for protecting puppies against canine herpesvirosis.
  • domestic dogs are exposed to numerous other diseases, and the development of a vaccinal vector capable of expressing different antigens of canine pathogenic agents would enable the efficacy of vaccination programmes to be simplified and improved, especially for puppies in breeding kennels.
  • pathogenic agents of importance for dogs the Carre's disease virus, the Rubarth's hepatitis virus, the rabies virus, the canine parvovirosis virus, the canine coronavirus, the parainfluenza virus type 2, Bordetella bronchiseptica, Borrelia burgdorferi, Leptospira spp. and Leishmania infantum may be mentioned.
  • the inventors have succeeded in determining several regions which are non-essential for replication in vitro, which have proved useful for the construction of recombinant CHV viruses.
  • the inventors are hence in a position to put forward for the first time the CHV virus as a vaccination vector for dogs.
  • the vaccinal vectors according to the invention had particular advantages for the vaccination of dogs.
  • the canine herpesvirus is very species-specific and possesses a large genome containing several potential insertion sites and permitting the simultaneous insertion of several expression cassettes for foreign genes. This affords the possibility of vaccinating dogs at the same time against different canine pathogenic agents using a single recombinant virus.
  • the main objective of the invention is to provide a vaccinal vector permitting the expression of immunogens of canine pathogens for the purpose of protecting dogs against the main canine infectious diseases.
  • Another objective of the invention is to provide such a vector permitting the vaccination of dogs, and especially puppies having maternal antibodies, via the mucosal, in particular the oral, nasal or conjunctival, route.
  • Yet another objective of the invention is to provide such a vector which permits vaccination at the same time against herpesvirosis in puppies.
  • the subject of the present invention is a recombinant live vaccine using as vector a canine herpesvirus comprising and expressing at least one nucleotide sequence coding for a polypeptide, this sequence being inserted into a site which is non-essential for replication in vitro.
  • the inventors have isolated and analysed a genomic fragment of the CHV virus, on which they have characterized 5 open reading frames (ORF1 to ORF5), among which two (ORF3 and ORF5) have proved to be non-essential for replication in vitro. Moreover, the inventors have found that other regions of the CHV genome could also be used to insert foreign genes. These insertion sites are: thymidine kinase gene (CHV TK ORF) (Rémond M. et al. Virus Research. 1995. 39. 341-354.) and sequence situated between the CHV ORF19 and the CHV ORF22 (Rémond M. et al. J. Gen. Virol. 1996. 76. 37-48). These sites are described more precisely in the examples of the present invention.
  • CHV TK ORF thymidine kinase gene
  • the inserted sequence codes for an antigenic polypeptide, and preferentially for an antigenic polypeptide of a canine pathogenic agent. It is also possible to insert the sequences coding for immunomodulatory proteins such as cytokines. According to an advantageous variant, it is possible to use in combination a sequence coding for a cytokine, or the like, and a sequence coding for an antigen. If need be, several cytokine sequences can be used in combination with one another, optionally in combination with one or more sequences coding for antigens.
  • the insertion into the sites is carried out by simple insertion (without deletion), or after partial or total deletion of the ORF or ORFs used as insertion sites.
  • CHV strain F205 which was isolated by L. Carmichael (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650).
  • CMV IE promoter is understood to mean, in particular, a fragment such as is given in the examples, as well as the subfragments thereof retaining the same promoter activity.
  • the CMV IE promoter can be the human (HCMV IE) promoter or the murine (MCMV IE) promoter, or alternatively a CMV IE promoter of another origin, for example rat, guinea pig or porcine CMV.
  • At least two nucleotide sequences may be inserted into one site under the control of different promoters.
  • the latter may be, in particular, CMV IE promoters of different origins.
  • another promoter is used in combination with the CMV IE promoter in such a way that the two promoters have their 5′ ends adjacent and that the transcriptions initiated from these two promoters take place in opposite directions.
  • This particular arrangement enables two nucleotide sequences to be inserted into the same site, one under the control of the CMV IE promoter and the other under that of the promoter used in combination with it.
  • This construction is noteworthy from the fact that the presence of the CMV IE promoter, and in particular of its enhancer portion, can activate the transcription induced by the promoter used in combination.
  • a promoter used in combination there may be mentioned, for example, a CMV promoter of different species from the first promoter. It is also possible to envisage other promoters, such as the Marek's disease virus (MDV) RNA1.8 promoter (G. Bradley et al. J. Virol. 1989. 63. 2534-2542).
  • MDV Marek's disease virus
  • the nucleotide sequence inserted into the CHV vector in order to be expressed can be any sequence coding for an antigenic polypeptide of a canine pathogenic agent capable, when expressed under the favourable conditions obtained by the invention, of bringing about an immunization leading to an effective protection of the vaccinated animal against the pathogenic agent.
  • the nucleotide sequences coding for the antigens of interest for a given disease, in particular the viral, bacterial or parasitic diseases mentioned above, may hence be inserted under the conditions described by the present invention.
  • CDV Carré's disease virus
  • nucleotide sequences coding for antigens or fragments of antigens of the rabies virus especially the G gene (Patents FR-A-2,515,685 and EP-A-162,757), of the canine parvovirosis virus (VP2 gene) (Parrish C. et al. J. Virol. 1991. 65. 6544-6552) or of the parainfluenza virus type 2 (HA and/or F genes).
  • VP2 gene canine parvovirosis virus
  • HA and/or F genes parainfluenza virus type 2
  • sequences coding for Borrelia burgdorferi antigens especially the genes coding for the OspA and OspB antigens (Bergström S. et al. Mol. Microbiol. 1989. 3. 479-486).
  • a typical case of the invention is a vaccine comprising a nucleotide sequence coding for an antigen of the Carré's disease virus under the control of CMV IE, and a nucleotide sequence coding for an antigen of another canine viral disease, in particular the ones mentioned above, under the control of the other promoter.
  • heterologous sequences and their associated promoters may be inserted more conventionally in tandem into the insertion locus, that is to say according to the same transcription direction.
  • IVS internal ribosome entry site
  • SVDV swine vesicular disease virus
  • EMCV encephalomyocarditis virus
  • FMDV aphthous fever virus
  • the cassette for expression of two genes would hence have the following minimum structure: promoter—gene 1—IRES—gene 2—polyadenylation signal.
  • the recombinant live vaccine according to the invention may hence comprise, inserted into the insertion locus, an expression cassette comprising in succession a promoter, two or more genes separated in pairs by an IRES, and a polyadenylation signal.
  • insertion into the locus it is possible to carry out one or more other insertions, one or more mutations or one or more deletions elsewhere in the genome. In all cases, insertion into a locus other than the one described in the invention enables other genes to be expressed.
  • the use of the recombinant viruses according to the invention enables dogs to be protected against one or more of the diseases mentioned above, and at the same time against canine herpesvirosis.
  • the subject of the present invention is also a polyvalent vaccine formula comprising, as a mixture or to be mixed, at least two recombinant live vaccines as defined above, these vaccines comprising different inserted sequences isolated, in particular, from different pathogens.
  • These vaccine formulae contain dosages and/or vehicles which are suited to the administration route.
  • the subject of the present invention is also CHV viruses modified in at least one of the sites indicated.
  • Its subject is also a method of vaccination, especially of dogs, in which an effective amount of a vaccine as defined above is administered via any parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route.
  • the vaccinal dose will preferably be between 10 2 CCID50 and 10 7 CCID50.
  • the dose for the parenteral route will be between 10 4 CCID50 and 10 7 CCID50, and for the oral and/or nasal route, between 10 2 CCID50 and 10 5 CCID50.
  • the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.
  • the subject of the present invention is also the DNA fragments comprising all or part of the sequence defined by positions 1 to 6216 on SEQ ID No. 1 ( FIG. 1 ), in particular all or part of the ORF3 site defined and/or of the flanking sequences located upstream and downstream of this site, which fragments will be useful as flanking arms for the techniques of homologous recombination with the genome of the CHV virus chosen as parent virus.
  • the invention also relates to the variants of these fragments which correspond to the equivalent sequences of the other strains of CHV.
  • the expert is entirely free to choose the regions serving as flanking arms in connection with the type of insertion (with or without deletion) or of deletion (partial or total) chosen.
  • the flanking arms may thus have from 100 to 800 base pairs, but can be larger if necessary.
  • a further subject of the invention is a method of preparation of the vectors and vaccines according to the invention, as emerges from the description of the vaccines, by insertion of genes of interest into the insertion site.
  • FIG. 1 Sequence of the CHV region (6216 base pairs) and translation of the different open reading frames (ORFs) present in this sequence (ORF1 to ORF5).
  • FIG. 2 Plasmid pPB200 (donor plasmid for the insertion of expression cassettes into the CHV ORF3 site).
  • FIG. 3 Construction of the plasmid pP3202 (donor plasmid for the insertion of expression cassettes into the CHV ORF5 site).
  • FIG. 4 Construction of the plasmid pPB204 (donor plasmid for the insertion of expression cassettes into the CHV TK site).
  • FIG. 5 Construction of the plasmid pPB206 (donor plasmid for the insertion of expression cassettes into the site situated between the CHV ORF19 and CHV ORF22 genes).
  • FIG. 6 Construction of the plasmid pPB208 (expression cassette for the CDV HA gene).
  • FIG. 7 Construction of the plasmid pPB210 (expression cassette for the CDV F gene).
  • FIG. 8 Construction of the plasmid pPB213 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site).
  • FIG. 9 Construction of the plasmid pPB214 (donor plasmid for the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site).
  • FIG. 10 Plasmid pPB200′
  • FIG. 11 Construction of the plasmid pPB212 (cassette for the expression of the rabies virus G gene).
  • FIG. 12 Construction of the plasmid pPB125 (donor plasmid for the insertion of the cassette for the expression of the rabies virus G gene into the CHV ORF3 site).
  • FIG. 13 Construction of the plasmid pPB216 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site).
  • FIG. 14 Construction of the plasmid pPB217 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site).
  • FIG. 15 Construction of the plasmid pPB218 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes).
  • the virus used as parent virus is the canine herpesvirus strain F205 (also known as the Carmichael strain). This strain was obtained from Dr. L. Carmichael (Cornell University, NY), who isolated it and described its biological characteristics (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650).
  • the conditions of culture of this virus are as follows: MDCK (Madin-Darby canine kidney ATCC CCL34) cells cultured in Eagle's minimum essential medium (MEM medium) are inoculated with the CHV strain F205 using a multiplicity of infection of 1. The infected cells are then incubated at 37° C. for approximately 36 hours until a complete cytopathic effect is seen.
  • the supernatant and the lysed cells are harvested, and the whole of the viral suspension is centrifuged at 1000 g for 10 minutes at +4° C. to remove cell debris.
  • the viral particles are then harvested by ultracentrifugation at 400,000 g for 1 hour at +4° C.
  • the pellet is taken up in a minimum volume of buffer (10 mM Tris, 1 mM EDTA).
  • This concentrated viral suspension is treated with proteinase K (100 ⁇ g/ml final) in the presence of sodium dodecyl sulphate (SDS) (0.5% final) for 2 hours at 37° C.
  • SDS sodium dodecyl sulphate
  • the viral DNA is then extracted with a phenol/chloroform mixture and thereafter precipitated with 2 volumes of absolute ethanol. After one night at ⁇ 20° C., the precipitated DNA is centrifuged at 10,000 g for 15 minutes at +4° C. The DNA pellet is dried and then taken up in a minimum volume of sterile ultra
  • the purified genomic DNA of the CHV virus strain F205 was digested with the restriction enzymes ScaI and XhoI, and the approximately 6200-bp ScaI-XhoI fragment was cloned into the vector pBlueScript SKII+ (Stratagene Ref. 212205), previously digested with ScaI and XhoI, to give the plasmid pPB154.
  • the XhoI-ScaI fragment cloned into plasmid pPB154 was sequenced completely on both strands to generate the 6216-bp sequence of FIG. 1 (SEQ ID No. 1).
  • FIG. 1 Several open reading frames larger than 65 amino acids in size were identified on this sequence ( FIG. 1 ):
  • the first reading frame (ORF1) (positions 1353-157) occurs on the complementary strand and codes for a polypeptide of 398 amino acids (SEQ ID No. 2).
  • the second reading frame (ORF2) (positions 1708-2970) codes for a polypeptide of 420 amino acids (SEQ ID No. 3).
  • the third reading frame (ORF3) (positions 3040-4242) codes for a polypeptide of 400 amino acids (SEQ ID No. 4).
  • the fourth reading frame (positions 4374-5753) codes for a polypeptide of 459 amino acids (SEQ ID No. 5).
  • the fifth reading frame (ORF5) (positions 5872-6216) is incomplete and codes for a truncated protein of 115 amino acids (SEQ ID No. 6).
  • Plasmid pPB154 (9121 bp) (Example 2) was digested with HindIII and SpeI to isolate the 620-bp HindIII-SpeI fragment (fragment A). Plasmid pPB154 was digested with EcoRI and SpeI to isolate the 659-bp EcoRI-SpeI fragment (fragment B). The fragments A and B were ligated together with the vector pGEM4Z (Promega Ref. P2161), previously digested with EcoRI and HindIII, to give the plasmid pPB199 (4096 bp).
  • pGEM4Z Promega Ref. P2161
  • Plasmid pPB199 was then digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA070 (33 mer) (SEQ ID No. 7) 5′ CTAGTCCAGCAAGGTGGATCGATATCGGGCCCA 3′ JCA071 (33 mer) (SEQ ID No. 8) 5′ CTAGTGGGCCCGATATCGATCCACCTTGCTGGA 3′ to give plasmid pPB200 (4129 bp).
  • the sequence of the CHV ORF5 gene was published recently (Limbach K. et al. J. Gen. Virol. 1994. 75. 2029-2039).
  • a PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides: JCA072 (22 mer) (SEQ ID No. 9) 5′ CAGCTTTATGTTTTTATTGTTC 3′ JCA073 (29 mer) (SEQ ID No. 10) 5′ AAAGAATTCTACAACTGTTTAATAAAGAC 3′
  • Plasmid pPB201 was then digested with ScaI and PvuII and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA074 (36 mer) (SEQ ID No.
  • TK CHV thymidine kinase
  • This fragment was digested with HpaI and HindIII to isolate a 1019-bp HpaI-HindIII fragment.
  • This fragment was ligated with the vector pSP73 (Promega Ref. P2221), previously digested with EcoRV and HindIII, to give the plasmid pPB203 (3423 bp).
  • Plasmid pPB203 was then digested with EcoRI and StyI and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA078 (36 mer) (SEQ ID No. 15) 5′ AATTCCCAGCTACATGGGATATCGGGCCCATCGATC 3′ JCA079 (36 mer) (SEQ ID No. 16) 5′ CAAGGATCGATGGGCCCGATATCCCATGTAGCTGGG 3′ to give plasmid pPB204 (3399 bp).
  • a PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides: JCA080 (36 mer) (SEQ ID No. 17) 5′ GGAGATCTAGTAAATTAAATAGTAATTCATTTAATG 3′ JCA081 (33 mer) (SEQ ID No. 18) 5′ CAGTCGCGAAGATGAAAATAAAATCCATCGAAG 3′
  • Plasmid pPB205 was then digested with MfeI and thereafter partially digested with SspI in order to isolate the 3512-bp MfeI-SspI fragment.
  • JCA082 38 mer
  • SEQ ID No. 19 5′ AATTGGCAGCTACATGGGATATCGGGCCCATCGATAAT 3′ JCA083 (34 mer)
  • JCA083 34 mer
  • SEQ ID No. 20 5′ ATTATCGATGGGCCCGATATCGGATGTAGCTGGC 3′ to give plasmid pPB206 (3548 bp).
  • the CDV strain Onderstepoort (Mitchell W. et al. J. Virol. Meth. 1987. 18. 121-131) was cultured on MDCK (Madin-Darby canine kidney) cells in DMEM medium (Gibco). After purification of the virus, the genomic viral RNA was isolated using the guanidinium thiocyanate/phenol-chloroform extraction technique (Chomczynski P. and Sacchi N., Anal. Biochem. 1987. 162. 156-159).
  • oligonucleotides containing restriction sites at their 5′ ends to facilitate the cloning of the amplified fragments
  • the reverse transcription (RT) reaction and polymerase chain amplification (PCR) were performed according to the standard techniques (Sambrook J. et al. 1989). Each RT-PCR reaction was carried out with a pair of specific amplimers and taking as template the extracted viral genomic RNA.
  • the amplified complementary DNA was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) before being digested with the restriction enzymes and cloned into the appropriate vector.
  • the plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
  • the fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Cat # P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB207 (5634 bp).
  • a PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides: PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′ PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′ to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment.
  • Plasmid PCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
  • the fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Ref. P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB209 (5808 bp).
  • PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides: PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′ PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′ to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB209, previously digested with KpnI, to give plasmid pPB210 (6041 bp).
  • Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus HA gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB213 (7043 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site.
  • Plasmid pPB210 (Example 7.2.) was digested with ApaI and ClaI to isolate a 3100-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus F gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB214 (7217 bp). This plasmid permits the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site.
  • Plasmid pPB199 (Example 3) was digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides: JCA088 (39 mer) (SEQ ID No. 27) 5′ CTAGTCCAGCAAGGTGTCGACGGATCGATATCGGGCCCA 3′ JCA089 (39 mer) (SEQ ID No. 28) 5′ CTAGTGGGCCCGATATCGATCCGTCGACACCTTGCTGGA 3′ to give plasmid pPB200′ (4135 bp) ( FIG. 10 ).
  • Plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
  • RNA of the rabies virus ERA strain was extracted and purified from a culture of rabies virus-infected Vero cells. An RT-PCR reaction was then carried out (see Example 7) with the genomic RNA of the rabies virus (strain ERA) and with the following oligonucleotides: JCA090 (31 mer) (SEQ ID No. 29) 5′ TTGCGGCCGCATGGTTCCTCAGGCTCTCCTG 3′ JCA091 (31 mer) (SEQ ID No.
  • a PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides: PB088 (30 mer) (SEQ ID No. 23) 5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′ PB089 (32 mer) (SEQ ID No. 24) 5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′ to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment.
  • Plasmid pPB212 was digested with EcoRV and SalI to isolate a 2664-bp EcoRV-SalI fragment containing the cassette for the expression of the rabies virus G gene. This fragment was then ligated with plasmid pPB200′ (see above), previously digested with EcoRV and SalI, to give plasmid pPB215 (6790 bp) ( FIG. 12 ).
  • Plasmid pPB208 (Example 7.1.) was digested with SmaI and ApaI to isolate a 2909-bp SmaI-ApaI fragment containing the cassette for the expression of the CDV HA gene. This fragment was then ligated with plasmid pPB202 (Example 4), previously digested with EcoRV and ApaI, to give plasmid pPB216 (6291 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site.
  • Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB204 (Example 5), previously digested with ApaI and ClaI, to give plasmid pPB217 (6316 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site.
  • Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB206 (Example 6), previously digested with ApaI and ClaI, to give plasmid pPB218 (6462 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes.
  • Plasmid pPB213 (see Example 8) was linearized by digestion with HindIII, extracted with a phenol-chloroform mixture, precipitated with absolute ethanol and then taken up in sterile water.
  • the cells were then left in culture for 24 hours at +37° C. After 24 hours to 48 hours of culture, 1 ml of culture supernatant was harvested, and several dilutions of this supernatant were used to infect other MDCK cells (cultured in Petri dishes (Corning 4.5 cm in diameter)) so as to obtain isolated plaques, each dish being infected with 1 ml of a dilution of the initial supernatant. After contact for 1 hour at 37° C., the infection medium was removed and replaced by 5 ml of MEM medium containing 1% of agarose, kept supercooled at 42° C. When the agarose had solidified, the dishes were incubated for 48 hours at 37° C. in a CO 2 incubator until plaques were seen.
  • the agarose layer was then removed, and a transfer of the viral plaques was carried out onto a sterile nitrocellulose membrane of the same diameter as the Petri dish used for culturing. This membrane was itself transferred onto another nitrocellulose membrane so as to obtain an inverted “copy” of the first transfer.
  • the plaques transferred onto this second copy were then hybridized, according to the standard techniques known to a person skilled in the art, with a 1842-bp NotI-NotI fragment of the CDV HA gene, obtained by digestion of plasmid pPB208 (Example 7.1.), labelled with digoxigenin (DNA Labelling kit, Boehringer Mannheim, CAT # 1175033).
  • the nitrocellulose membrane was placed in contact with an autoradiographic film.
  • the images of positive hybridization on this membrane indicated which plaques were the ones which contained recombinant CHV viruses which had inserted the CDV HA cassette.
  • the plaques corresponding to these positive plaques were cut out under sterile conditions from the first nitrocellulose membrane, placed in an Eppendorf tube containing 0.5 ml of MEM medium and sonicated to release the virions from the membrane.
  • the medium contained in the Eppendorf tube was then diluted in MEM medium, and the dilutions thereby obtained were used to infect further cultures of MDCK cells.
  • a 100% pure recombinant virus containing the HCMV-IE/CDV HA/polyA cassette inserted into the ORF3 site was thereby isolated after 3 cycles of purification, and was called vCHV01.
  • the homology of the recombination was verified by PCR using oligonucleotides situated on each side of the insertion site.
  • Example 14 the construction of different recombinant CHV viruses is carried out using the donor plasmids described in Examples 9 to 13.
  • the recombinant viruses obtained in Examples 14 and 15 are cultured on MDCK cells. Harvesting of the recombinant virus takes place when the cytopathic effect is complete. The lysed cells and the culture supernatant are harvested. After clarification of the cell lysate to remove cell debris, the viral solution is titrated. The viral solution is then diluted in a stabilizing solution for lyophilization, distributed on the basis of one vaccinal dose (10 2 CCID50 to 10 7 CCID50) per vial and lastly lyophilized. The viral solution can then be frozen if necessary.
  • the vaccine obtained according to the invention is redissolved or thawed, and then administered via the parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route.
  • the vaccinal dose will preferably be between 10 2 CCID50 and 10 7 CCID50.
  • the dose for the parenteral route will be between 10 4 CCID50 and 10 7 CCID50, and for the oral and/or nasal route, between 10 2 CCID50 and 10 5 CCID50.
  • the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed and claimed is a recombinant canine herpes virus (CHV). The recombinant CHV includes and expresses at least one heterologous nucleotide sequence encoding an antigen. The antigen can be canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, or Borrelia burgdorferi OspB. The at least one heterologous nucleotide sequence can be in at least one insertion site selected from the group consisting of ORF3 (SEQ ID NO:4), ORF5 (SEQ ID NO:5), the thymidine kinase gene, and the intergenic region corresponding to genes coding for the large subunit and the small subunit. Immunological or vaccine compositions as well as methods for inducing an immunological response are also disclosed and claimed.

Description

  • The present invention relates to vaccines, preferably for dogs, produced from recombinant canine herpesviruses, and to the methods for obtaining and preparing these recombinant viruses. The present invention relates more especially to recombinant canine herpesviruses comprising an expression cassette for one or more foreign gene(s).
  • Canine herpesvirosis is caused by the canine herpesvirus (CHV). The canine herpesvirus (CHV) is classified in the Alphaherpesvirinae family. This herpesvirus is a major pathogen for neonatal puppies. Canine herpesvirosis manifests itself chiefly in a haemorrhagic disease in puppies, and in a benign disease of the upper respiratory apparatus in adult dogs. There are at present no vaccines for protecting puppies against canine herpesvirosis.
  • Moreover, domestic dogs are exposed to numerous other diseases, and the development of a vaccinal vector capable of expressing different antigens of canine pathogenic agents would enable the efficacy of vaccination programmes to be simplified and improved, especially for puppies in breeding kennels. Among pathogenic agents of importance for dogs, the Carre's disease virus, the Rubarth's hepatitis virus, the rabies virus, the canine parvovirosis virus, the canine coronavirus, the parainfluenza virus type 2, Bordetella bronchiseptica, Borrelia burgdorferi, Leptospira spp. and Leishmania infantum may be mentioned.
  • Little is known about the CHV virus genome. The genomic organization of this virus was published only recently (Rémond M. et al. J. Gen. Virol. 1996. 77. 37-48), and the genes for the three major glycoproteins gB, gC and gD, as well as a gene designated CHV ORF2, have been described (K. Limbach et al. J. Gen. Virol. 1994. 75. 2029-2039).
  • Following their work on CHV, the inventors have succeeded in determining several regions which are non-essential for replication in vitro, which have proved useful for the construction of recombinant CHV viruses. The inventors are hence in a position to put forward for the first time the CHV virus as a vaccination vector for dogs. It was found that the vaccinal vectors according to the invention had particular advantages for the vaccination of dogs. In effect, the canine herpesvirus is very species-specific and possesses a large genome containing several potential insertion sites and permitting the simultaneous insertion of several expression cassettes for foreign genes. This affords the possibility of vaccinating dogs at the same time against different canine pathogenic agents using a single recombinant virus.
  • The main objective of the invention is to provide a vaccinal vector permitting the expression of immunogens of canine pathogens for the purpose of protecting dogs against the main canine infectious diseases.
  • Another objective of the invention is to provide such a vector permitting the vaccination of dogs, and especially puppies having maternal antibodies, via the mucosal, in particular the oral, nasal or conjunctival, route.
  • Yet another objective of the invention is to provide such a vector which permits vaccination at the same time against herpesvirosis in puppies.
  • Hence the subject of the present invention is a recombinant live vaccine using as vector a canine herpesvirus comprising and expressing at least one nucleotide sequence coding for a polypeptide, this sequence being inserted into a site which is non-essential for replication in vitro.
  • The inventors have isolated and analysed a genomic fragment of the CHV virus, on which they have characterized 5 open reading frames (ORF1 to ORF5), among which two (ORF3 and ORF5) have proved to be non-essential for replication in vitro. Moreover, the inventors have found that other regions of the CHV genome could also be used to insert foreign genes. These insertion sites are: thymidine kinase gene (CHV TK ORF) (Rémond M. et al. Virus Research. 1995. 39. 341-354.) and sequence situated between the CHV ORF19 and the CHV ORF22 (Rémond M. et al. J. Gen. Virol. 1996. 76. 37-48). These sites are described more precisely in the examples of the present invention.
  • Preferably, the inserted sequence codes for an antigenic polypeptide, and preferentially for an antigenic polypeptide of a canine pathogenic agent. It is also possible to insert the sequences coding for immunomodulatory proteins such as cytokines. According to an advantageous variant, it is possible to use in combination a sequence coding for a cytokine, or the like, and a sequence coding for an antigen. If need be, several cytokine sequences can be used in combination with one another, optionally in combination with one or more sequences coding for antigens.
  • The insertion into the sites is carried out by simple insertion (without deletion), or after partial or total deletion of the ORF or ORFs used as insertion sites.
  • As a parent virus for the construction of recombinant CHV viruses, it is possible to use, in particular, the CHV strain F205 which was isolated by L. Carmichael (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650).
  • For the expression of foreign genes inserted into the CHV genome according to the present invention, it will be preferable to use a strong eukaryotic promoter such as, preferentially, a cytomegalovirus (CMV) immediate-early (IE) promoter. CMV IE promoter is understood to mean, in particular, a fragment such as is given in the examples, as well as the subfragments thereof retaining the same promoter activity. The CMV IE promoter can be the human (HCMV IE) promoter or the murine (MCMV IE) promoter, or alternatively a CMV IE promoter of another origin, for example rat, guinea pig or porcine CMV.
  • At least two nucleotide sequences may be inserted into one site under the control of different promoters. The latter may be, in particular, CMV IE promoters of different origins.
  • According to an advantageous development of the invention, another promoter is used in combination with the CMV IE promoter in such a way that the two promoters have their 5′ ends adjacent and that the transcriptions initiated from these two promoters take place in opposite directions. This particular arrangement enables two nucleotide sequences to be inserted into the same site, one under the control of the CMV IE promoter and the other under that of the promoter used in combination with it. This construction is noteworthy from the fact that the presence of the CMV IE promoter, and in particular of its enhancer portion, can activate the transcription induced by the promoter used in combination. As a promoter used in combination, there may be mentioned, for example, a CMV promoter of different species from the first promoter. It is also possible to envisage other promoters, such as the Marek's disease virus (MDV) RNA1.8 promoter (G. Bradley et al. J. Virol. 1989. 63. 2534-2542).
  • The nucleotide sequence inserted into the CHV vector in order to be expressed can be any sequence coding for an antigenic polypeptide of a canine pathogenic agent capable, when expressed under the favourable conditions obtained by the invention, of bringing about an immunization leading to an effective protection of the vaccinated animal against the pathogenic agent. The nucleotide sequences coding for the antigens of interest for a given disease, in particular the viral, bacterial or parasitic diseases mentioned above, may hence be inserted under the conditions described by the present invention.
  • The typical case of the invention is the insertion of at least one nucleotide sequence coding appropriately for a polypeptide of the Carré's disease virus (canine distemper virus=CDV), and preferably for the CDV polypeptide HA (Sidhu M. et al., Virology. 1993. 193. 66-72) or for the CDV polypeptide F (Barrett T. et al. Virus Research. 1987. 8. 373-386). It is also possible to insert both of these genes together into the CHV vector. A recombinant live vaccine bringing about protection against Carré's disease is thereby obtained.
  • Other preferred cases of the invention are the insertion of nucleotide sequences coding for antigens or fragments of antigens of the rabies virus, especially the G gene (Patents FR-A-2,515,685 and EP-A-162,757), of the canine parvovirosis virus (VP2 gene) (Parrish C. et al. J. Virol. 1991. 65. 6544-6552) or of the parainfluenza virus type 2 (HA and/or F genes). It is also possible to insert sequences coding for Borrelia burgdorferi antigens, especially the genes coding for the OspA and OspB antigens (Bergström S. et al. Mol. Microbiol. 1989. 3. 479-486).
  • A typical case of the invention is a vaccine comprising a nucleotide sequence coding for an antigen of the Carré's disease virus under the control of CMV IE, and a nucleotide sequence coding for an antigen of another canine viral disease, in particular the ones mentioned above, under the control of the other promoter.
  • Naturally, the heterologous sequences and their associated promoters may be inserted more conventionally in tandem into the insertion locus, that is to say according to the same transcription direction.
  • The expression of several heterologous genes inserted into the insertion locus can also be possible by insertion of a sequence known as an “IRES” (internal ribosome entry site) originating, in particular, from a picornavirus such as the swine vesicular disease virus (SVDV; B.-F. Chen et al., J. Virology, 1993, 67, 2142-2148), the encephalomyocarditis virus (EMCV; R. J. Kaufman et al., Nucleic Acids Research, 1991, 19, 4485-4490) or the aphthous fever virus (FMDV; N. Luz and E. Beck, J. Virology, 1991, 65, 6486-6494), or alternatively of another origin. The content of these three papers is incorporated by reference. The cassette for expression of two genes would hence have the following minimum structure: promoter—gene 1—IRES—gene 2—polyadenylation signal. The recombinant live vaccine according to the invention may hence comprise, inserted into the insertion locus, an expression cassette comprising in succession a promoter, two or more genes separated in pairs by an IRES, and a polyadenylation signal.
  • In addition to the insertion into the locus according to the invention, it is possible to carry out one or more other insertions, one or more mutations or one or more deletions elsewhere in the genome. In all cases, insertion into a locus other than the one described in the invention enables other genes to be expressed.
  • The use of the recombinant viruses according to the invention enables dogs to be protected against one or more of the diseases mentioned above, and at the same time against canine herpesvirosis.
  • The subject of the present invention is also a polyvalent vaccine formula comprising, as a mixture or to be mixed, at least two recombinant live vaccines as defined above, these vaccines comprising different inserted sequences isolated, in particular, from different pathogens. These vaccine formulae contain dosages and/or vehicles which are suited to the administration route.
  • The subject of the present invention is also CHV viruses modified in at least one of the sites indicated.
  • Its subject is also a method of vaccination, especially of dogs, in which an effective amount of a vaccine as defined above is administered via any parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route. The vaccinal dose will preferably be between 102 CCID50 and 107 CCID50. Preferably, the dose for the parenteral route will be between 104 CCID50 and 107 CCID50, and for the oral and/or nasal route, between 102 CCID50 and 105 CCID50. As defined, the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.
  • The subject of the present invention is also the DNA fragments comprising all or part of the sequence defined by positions 1 to 6216 on SEQ ID No. 1 (FIG. 1), in particular all or part of the ORF3 site defined and/or of the flanking sequences located upstream and downstream of this site, which fragments will be useful as flanking arms for the techniques of homologous recombination with the genome of the CHV virus chosen as parent virus. Naturally, the invention also relates to the variants of these fragments which correspond to the equivalent sequences of the other strains of CHV. The expert is entirely free to choose the regions serving as flanking arms in connection with the type of insertion (with or without deletion) or of deletion (partial or total) chosen. Generally speaking, the flanking arms may thus have from 100 to 800 base pairs, but can be larger if necessary.
  • A further subject of the invention is a method of preparation of the vectors and vaccines according to the invention, as emerges from the description of the vaccines, by insertion of genes of interest into the insertion site.
  • The invention will now be described in greater detail by means of non-limiting examples of implementation, taken with reference to the drawing, wherein:
  • FIG. 1: Sequence of the CHV region (6216 base pairs) and translation of the different open reading frames (ORFs) present in this sequence (ORF1 to ORF5).
  • FIG. 2: Plasmid pPB200 (donor plasmid for the insertion of expression cassettes into the CHV ORF3 site).
  • FIG. 3: Construction of the plasmid pP3202 (donor plasmid for the insertion of expression cassettes into the CHV ORF5 site).
  • FIG. 4: Construction of the plasmid pPB204 (donor plasmid for the insertion of expression cassettes into the CHV TK site).
  • FIG. 5: Construction of the plasmid pPB206 (donor plasmid for the insertion of expression cassettes into the site situated between the CHV ORF19 and CHV ORF22 genes).
  • FIG. 6: Construction of the plasmid pPB208 (expression cassette for the CDV HA gene).
  • FIG. 7: Construction of the plasmid pPB210 (expression cassette for the CDV F gene).
  • FIG. 8: Construction of the plasmid pPB213 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site).
  • FIG. 9: Construction of the plasmid pPB214 (donor plasmid for the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site).
  • FIG. 10: Plasmid pPB200′
  • FIG. 11: Construction of the plasmid pPB212 (cassette for the expression of the rabies virus G gene).
  • FIG. 12: Construction of the plasmid pPB125 (donor plasmid for the insertion of the cassette for the expression of the rabies virus G gene into the CHV ORF3 site).
  • FIG. 13: Construction of the plasmid pPB216 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site).
  • FIG. 14: Construction of the plasmid pPB217 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site).
  • FIG. 15: Construction of the plasmid pPB218 (donor plasmid for the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes).
  • SEQ ID sequence listing for the constructions in the insertion sites of the CHV vector:
  • SEQ ID No. 1 Complete sequence of the CHV ORF1→ORF5 region depicted in FIG. 1
  • SEQ ID No. 2 ORF1 amino acid sequence of FIG. 1
  • SEQ ID No. 3 ORF2 amino acid sequence of FIG. 1
  • SEQ ID No. 4 ORF3 amino acid sequence of FIG. 1
  • SEQ ID No. 5 ORF4 amino acid sequence of FIG. 1
  • SEQ ID No. 6 (Partial) ORF5 amino acid sequence of FIG. 1
  • SEQ ID No. 7 oligonucleotide JCA070
  • SEQ ID No. 8 oligonucleotide JCA071
  • SEQ ID No. 9 oligonucleotide JCA072
  • SEQ ID No. 10 Oligonucleotide JCA073
  • SEQ ID No. 11 Oligonucleotide JCA074
  • SEQ ID No. 12 Oligonucleotide JCA075
  • SEQ ID No. 13 Oligonucleotide JCA076
  • SEQ ID No. 14 Oligonucleotide JCA077
  • SEQ ID No. 15 Oligonucleotide JCA078
  • SEQ ID No. 16 Oligonucleotide JCA079
  • SEQ ID No. 17 Oligonucleotide JCA080
  • SEQ ID No. 18 Oligonucleotide JCA081
  • SEQ ID No. 19 Oligonucleotide JCA082
  • SEQ ID No. 20 Oligonuc JCA083
  • SEQ ID No. 21 Oligonucleotide JCA084
  • SEQ ID No. 22 Oligonucleotide JCA085
  • SEQ ID No. 23 Oligonucleotide PB088
  • SEQ ID No. 24 Oligonucleotide PB089
  • SEQ ID No. 25 Oligonucleotide JCA086
  • SEQ ID No. 26 Oligonucleotide JCA087
  • SEQ ID No. 27 Oligonucleotide JCA088
  • SEQ ID No. 28 Oligonucleotide JCA089
  • SEQ ID No. 29 Oligonucleotide JCA090
  • SEQ ID No. 30 Oligonucleotide JCA091
  • EXAMPLES
  • All the constructions of plasmids were carried out using the standard techniques of molecular biology described by Sambrook J. et al. (Molecular Cloning: A Laboratory Manual. 2nd Edition. Cold Spring Harbor Laboratory. Cold Spring Harbor. N.Y. 1989). All the restriction fragments used for the present invention were isolated using the “Geneclean” kit (BIO 101 Inc. La Jolla, Calif.).
  • The virus used as parent virus is the canine herpesvirus strain F205 (also known as the Carmichael strain). This strain was obtained from Dr. L. Carmichael (Cornell University, NY), who isolated it and described its biological characteristics (Proc. Soc. Exp. Biol. Med. 1965. 120. 644-650). The conditions of culture of this virus are as follows: MDCK (Madin-Darby canine kidney ATCC CCL34) cells cultured in Eagle's minimum essential medium (MEM medium) are inoculated with the CHV strain F205 using a multiplicity of infection of 1. The infected cells are then incubated at 37° C. for approximately 36 hours until a complete cytopathic effect is seen.
  • Example 1
  • Extraction of Canine Herpesvirus DNA
  • After culture, the supernatant and the lysed cells are harvested, and the whole of the viral suspension is centrifuged at 1000 g for 10 minutes at +4° C. to remove cell debris. The viral particles are then harvested by ultracentrifugation at 400,000 g for 1 hour at +4° C. The pellet is taken up in a minimum volume of buffer (10 mM Tris, 1 mM EDTA). This concentrated viral suspension is treated with proteinase K (100 μg/ml final) in the presence of sodium dodecyl sulphate (SDS) (0.5% final) for 2 hours at 37° C. The viral DNA is then extracted with a phenol/chloroform mixture and thereafter precipitated with 2 volumes of absolute ethanol. After one night at −20° C., the precipitated DNA is centrifuged at 10,000 g for 15 minutes at +4° C. The DNA pellet is dried and then taken up in a minimum volume of sterile ultrapure water.
  • Example 2
  • Cloning and Characterization of the CHV ORF1-ORF5 Region
  • The purified genomic DNA of the CHV virus strain F205 was digested with the restriction enzymes ScaI and XhoI, and the approximately 6200-bp ScaI-XhoI fragment was cloned into the vector pBlueScript SKII+ (Stratagene Ref. 212205), previously digested with ScaI and XhoI, to give the plasmid pPB154.
  • The XhoI-ScaI fragment cloned into plasmid pPB154 was sequenced completely on both strands to generate the 6216-bp sequence of FIG. 1 (SEQ ID No. 1).
  • Several open reading frames larger than 65 amino acids in size were identified on this sequence (FIG. 1):
  • The first reading frame (ORF1) (positions 1353-157) occurs on the complementary strand and codes for a polypeptide of 398 amino acids (SEQ ID No. 2).
  • The second reading frame (ORF2) (positions 1708-2970) codes for a polypeptide of 420 amino acids (SEQ ID No. 3).
  • The third reading frame (ORF3) (positions 3040-4242) codes for a polypeptide of 400 amino acids (SEQ ID No. 4).
  • The fourth reading frame (ORF4) (positions 4374-5753) codes for a polypeptide of 459 amino acids (SEQ ID No. 5).
  • The fifth reading frame (ORF5) (positions 5872-6216) is incomplete and codes for a truncated protein of 115 amino acids (SEQ ID No. 6).
  • The different open reading frames are collated in the table below:
    Open reading Beginning-End Size in amino
    frame (positions in Figure 1) acids
    ORF
    1 1353-157  398 aa
    ORF 2 1708-2970 420 aa
    ORF
    3 3040-4242 400 aa
    ORF 4 4374-5753 459 aa
    ORF
    5 5872-6216 115 aa
  • Example 3
  • Construction of Plasmid pPB200 for the Insertion of Expression Cassettes Into the CIV ORF3 Site (FIG. 2)
  • Plasmid pPB154 (9121 bp) (Example 2) was digested with HindIII and SpeI to isolate the 620-bp HindIII-SpeI fragment (fragment A). Plasmid pPB154 was digested with EcoRI and SpeI to isolate the 659-bp EcoRI-SpeI fragment (fragment B). The fragments A and B were ligated together with the vector pGEM4Z (Promega Ref. P2161), previously digested with EcoRI and HindIII, to give the plasmid pPB199 (4096 bp). Plasmid pPB199 was then digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
    JCA070 (33 mer)
    (SEQ ID No. 7)
    5′ CTAGTCCAGCAAGGTGGATCGATATCGGGCCCA 3′
    JCA071 (33 mer)
    (SEQ ID No. 8)
    5′ CTAGTGGGCCCGATATCGATCCACCTTGCTGGA 3′

    to give plasmid pPB200 (4129 bp).
  • Example 4
  • Construction of Plasmid pPB202 for the Insertion of Expression Cassettes Into the CHV ORF5 Site (FIG. 3)
  • The sequence of the CHV ORF5 gene was published recently (Limbach K. et al. J. Gen. Virol. 1994. 75. 2029-2039). A PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides:
    JCA072 (22 mer)
    (SEQ ID No. 9)
    5′ CAGCTTTATGTTTTTATTGTTC 3′
    JCA073 (29 mer)
    (SEQ ID No. 10)
    5′ AAAGAATTCTACAACTGTTTAATAAAGAC 3′
  • to obtain a 751-bp PCR fragment containing the complete CHV ORF2 gene. This fragment was digested with BGlII and EcoRI to isolate a 709-bp BglII-EcoRI fragment. This fragment was ligated with the vector pGEM4Z (Promega Ref. P2161), previously digested with EcoRI and BamhI, to give the plasmid pPB201 (3559 bp). Plasmid pPB201 was then digested with ScaI and PvuII and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
    JCA074 (36 mer)
    (SEQ ID No. 11)
    5′ ACTCCAGCTACATGGGATATCGGGCCCATCGATCAG 3′
    JCA075 (36 mer)
    (SEQ ID No. 12)
    5′ CTGATCGATGGGCCCGATATCCCATGTAGCTGGAGT 3′

    to give plasmid pPB202 (3395 bp).
  • Example 5
  • Construction of Plasmid pPB204 for the Insertion of Expression Cassettes Into the CHV TK Site (FIG. 4)
  • The sequence of the CHV thymidine kinase (TK) gene was published recently (Rémond M. et al. Virus Research. 1995. 39. 341-354). A PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides:
    JCA076 (35 mer)
    (SEQ ID No. 13)
    5′ AGCGTTAACCTCAAAAGCCAAATTTACACTTCCCG 3′
    JCA077 (38 mer)
    (SEQ ID No. 14)
    5′ CCCAAGCTTTTCTAAAGCCCATTTATAAATAATAAATG 3′

    to obtain a 1030-bp PCR fragment containing the thymidine kinase (TK) gene. This fragment was digested with HpaI and HindIII to isolate a 1019-bp HpaI-HindIII fragment. This fragment was ligated with the vector pSP73 (Promega Ref. P2221), previously digested with EcoRV and HindIII, to give the plasmid pPB203 (3423 bp).
  • Plasmid pPB203 was then digested with EcoRI and StyI and thereafter ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
    JCA078 (36 mer)
    (SEQ ID No. 15)
    5′ AATTCCCAGCTACATGGGATATCGGGCCCATCGATC 3′
    JCA079 (36 mer)
    (SEQ ID No. 16)
    5′ CAAGGATCGATGGGCCCGATATCCCATGTAGCTGGG 3′

    to give plasmid pPB204 (3399 bp).
  • Example 6
  • Construction of Plasmid pPB206 for the Insertion of Expression Cassettes Into the Site Situated Between the CHV ORF19 and ORF22 Genes (FIG. 5)
  • The sequence of the intergenic region corresponding to the natural deletion of the genes coding for the large subunit (“RR1” gene) and for the small subunit (“RR2” gene) of ribonucleotide reductase was published recently (Rémond M. et al. J. Gen. Virol. 1996, 77. 37-48). According to the nomenclature used by Rémond et al., the deletion of these two genes occurs between the open reading frames designated CHV “orf19” and CHV “orf22” [designated herein ORF19 and ORF 22, respectively]. A PCR reaction was carried out with the genomic DNA of the CHV virus strain F205 (Example 1) and with the following oligonucleotides:
    JCA080 (36 mer)
    (SEQ ID No. 17)
    5′ GGAGATCTAGTAAATTAAATAGTAATTCATTTAATG 3′
    JCA081 (33 mer)
    (SEQ ID No. 18)
    5′ CAGTCGCGAAGATGAAAATAAAATCCATCGAAG 3′
  • to obtain a 720-bp PCR fragment containing the intergenic region corresponding to the natural deletion of the CHV ORF19 and ORF22 genes. This fragment was digested with SpeI and NruI to isolate a 709-bp SpeI-NruI fragment. This fragment was ligated with the vector pGEM4Z (Promega Ref. P2161), previously digested with SmaI and XbaI, to give the plasmid pPB205 (3572 bp). Plasmid pPB205 was then digested with MfeI and thereafter partially digested with SspI in order to isolate the 3512-bp MfeI-SspI fragment. This fragment was then ligated with a multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
    JCA082 (38 mer)
    (SEQ ID No. 19)
    5′ AATTGGCAGCTACATGGGATATCGGGCCCATCGATAAT 3′
    JCA083 (34 mer)
    (SEQ ID No. 20)
    5′ ATTATCGATGGGCCCGATATCGGATGTAGCTGGC 3′

    to give plasmid pPB206 (3548 bp).
  • Example 7
  • Isolation of the Genomic RNA of the CDV Strain Onderstepoort and Cloning of the Complementary DNA Coding for the HA and F Genes
  • The CDV strain Onderstepoort (Mitchell W. et al. J. Virol. Meth. 1987. 18. 121-131) was cultured on MDCK (Madin-Darby canine kidney) cells in DMEM medium (Gibco). After purification of the virus, the genomic viral RNA was isolated using the guanidinium thiocyanate/phenol-chloroform extraction technique (Chomczynski P. and Sacchi N., Anal. Biochem. 1987. 162. 156-159). Specific oligonucleotides (containing restriction sites at their 5′ ends to facilitate the cloning of the amplified fragments) were synthesized in such a way as to cover completely the coding regions of the genes which were to be amplified (HA and F genes, respectively). The reverse transcription (RT) reaction and polymerase chain amplification (PCR) were performed according to the standard techniques (Sambrook J. et al. 1989). Each RT-PCR reaction was carried out with a pair of specific amplimers and taking as template the extracted viral genomic RNA. The amplified complementary DNA was extracted with phenol/chloroform/isoamyl alcohol (25:24:1) before being digested with the restriction enzymes and cloned into the appropriate vector.
  • 7.1. Construction of the CDV HA Expression Cassette (pPB208) (FIG. 6)
  • The plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
  • An RT-PCR reaction was carried out with the genomic RNA of the CDV virus (strain Onderstepoort) and with the following oligonucleotides:
    JCA084 (32 mer)
    (SEQ ID No. 21)
    5′ TTGCGGCCGCATGCTCCCCTACCAAGACAAGG 3′
    JCA085 (28 mer)
    (SEQ ID No. 22)
    5′ TTGGTACCTTAACGGTTACATGAGAATC 3′

    to obtain a 1837-bp PCR fragment containing the CDV HA gene. This fragment was digested with NotI and KpnI to isolate a 1826-bp NotI-KpnI fragment (fragment B).
  • The fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Cat # P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB207 (5634 bp).
  • A PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides:
    PB088 (30 mer)
    (SEQ ID No. 23)
    5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′
    PB089 (32 mer)
    (SEQ ID No. 24)
    5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′

    to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB207, previously digested with KpnI, to give plasmid pPB208 (5867 bp).
    7.2. Construction of the CDV F Expression Cassette (pPB210) (FIG. 7)
  • Plasmid PCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
  • An RT-PCR reaction was carried out with the genomic RNA of the CDV virus (strain Onderstepoort) and with the following oligonucleotides:
    JCA086 (34 mer)
    (SEQ ID No. 25)
    5′ TTGCGGCCGCATGCACAGGGGAATCCCCAAAAGC 3′
    JCA087 (28 mer)
    (SEQ ID No. 26)
    5′ TTGGTACCTCAGAGTGATCTCACATAGG 3′

    to obtain a 2011-bp PCR fragment containing the CDV F gene. This fragment was digested with NotI and KpnI to isolate a 2000-bp NotI-KpnI fragment (fragment B). The fragments A and B were ligated together with the vector pGEM-7Zf+ (Promega Ref. P2251), previously digested with EcoRI and KpnI, to give the plasmid pPB209 (5808 bp).
  • A PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides:
    PB088 (30 mer)
    (SEQ ID No. 23)
    5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′
    PB089 (32 mer)
    (SEQ ID No. 24)
    5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′

    to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB209, previously digested with KpnI, to give plasmid pPB210 (6041 bp).
  • Example 8
  • Construction of the Donor Plasmid pPB213 for the Insertion of the CDV HA Expression Cassette Into the CHV ORF3 Site (FIG. 8)
  • Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus HA gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB213 (7043 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF3 site.
  • Example 9
  • Construction of the Donor Plasmid pPB214 for the Insertion of the CDV F Expression Cassette Into the CHV ORF3 Site (FIG. 9)
  • Plasmid pPB210 (Example 7.2.) was digested with ApaI and ClaI to isolate a 3100-bp ApaI-ClaI fragment containing the cassette for the expression of the CDV virus F gene. This fragment was then ligated with plasmid pPB200 (Example 3), previously digested with ApaI and ClaI, to give plasmid pPB214 (7217 bp). This plasmid permits the insertion of the cassette for the expression of the CDV F gene into the CHV ORF3 site.
  • Example 10
  • Construction of the Donor Plasmid pPB215 for the Insertion of the Cassette for the Expression of the Rabies Virus G Gene Into the CHV ORF3 Site (FIGS. 10, 11 and 12)
  • Plasmid pPB199 (Example 3) was digested with SpeI, treated with alkaline phosphatase and then ligated with the multiple cloning site obtained by hybridization of the following 2 oligonucleotides:
    JCA088 (39 mer)
    (SEQ ID No. 27)
    5′ CTAGTCCAGCAAGGTGTCGACGGATCGATATCGGGCCCA 3′
    JCA089 (39 mer)
    (SEQ ID No. 28)
    5′ CTAGTGGGCCCGATATCGATCCGTCGACACCTTGCTGGA 3′

    to give plasmid pPB200′ (4135 bp) (FIG. 10).
  • Plasmid pCMVB (Clontech Ref. 6177-1) was digested with EcoRI and NotI to isolate an 818-bp EcoRI-NotI fragment containing the promoter region of the human cytomegalovirus immediate-early gene (fragment A).
  • According to the technical procedures already described for the CDV virus (Example 7), the RNA of the rabies virus ERA strain was extracted and purified from a culture of rabies virus-infected Vero cells. An RT-PCR reaction was then carried out (see Example 7) with the genomic RNA of the rabies virus (strain ERA) and with the following oligonucleotides:
    JCA090 (31 mer)
    (SEQ ID No. 29)
    5′ TTGCGGCCGCATGGTTCCTCAGGCTCTCCTG 3′
    JCA091 (31 mer)
    (SEQ ID No. 30)
    5′ TTGGTACCTCACAGTCTGGTCTCACCCCCAC 3′

    to obtain a 1597-bp PCR fragment containing the rabies virus G gene (Patents FR-A-2,515,685 and EP-A-162,757). This fragment was digested with NotI and KpnI to isolate a 1586-bp NotI-KpnI fragment (fragment B). The fragments A and B were ligated together with the vector pSP73 (Promega Ref. P2221), previously digested with EcoRI and KpnI, to give the plasmid pPB211 (4852 bp).
  • A PCR reaction was carried out with plasmid pCMVB and with the following oligonucleotides:
    PB088 (30 mer)
    (SEQ ID No. 23)
    5′ TTGGGTACCGCCTCGACTCTAGGCGGCCGC 3′
    PB089 (32 mer)
    (SEQ ID No. 24)
    5′ TTGGGTACCGGATCCGAAAAAACCTCCCACAC 3′

    to obtain a 244-bp PCR fragment containing the polyadenylation signal of the SV40 virus early gene. This fragment was digested with KpnI to isolate a 233-bp KpnI-KpnI fragment. This fragment was then ligated with plasmid pPB211, previously digested with KpnI, to give plasmid pPB212 (5085 bp) (FIG. 11). Plasmid pPB212 was digested with EcoRV and SalI to isolate a 2664-bp EcoRV-SalI fragment containing the cassette for the expression of the rabies virus G gene. This fragment was then ligated with plasmid pPB200′ (see above), previously digested with EcoRV and SalI, to give plasmid pPB215 (6790 bp) (FIG. 12).
  • Example 11
  • Construction of the Donor Plasmid pPB216 for the Insertion of the CDV HA Expression Cassette Into the CHV ORF5 Site (FIG. 13)
  • Plasmid pPB208 (Example 7.1.) was digested with SmaI and ApaI to isolate a 2909-bp SmaI-ApaI fragment containing the cassette for the expression of the CDV HA gene. This fragment was then ligated with plasmid pPB202 (Example 4), previously digested with EcoRV and ApaI, to give plasmid pPB216 (6291 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV ORF5 site.
  • Example 12
  • Construction of the Donor Plasmid pPB217 for the Insertion of the CDV EA Expression Cassette Into the CHV TK Site (FIG. 14)
  • Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB204 (Example 5), previously digested with ApaI and ClaI, to give plasmid pPB217 (6316 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the CHV TK site.
  • Example 13
  • Construction of the Donor Plasmid pPB218 for the Insertion of the CDV HA Expression Cassette Into the Site Situated Between the CHV ORF19 and CHV ORF22 Genes (FIG. 15)
  • Plasmid pPB208 (Example 7.1.) was digested with ApaI and ClaI to isolate a 2920-bp fragment containing the cassette for the expression of the CDV HA gene. This fragment was ligated with plasmid pPB206 (Example 6), previously digested with ApaI and ClaI, to give plasmid pPB218 (6462 bp). This plasmid permits the insertion of the cassette for the expression of the CDV HA gene into the site situated between the CHV ORF19 and CHV ORF22 genes.
  • Example 14
  • Isolation of the Recombinant Virus vCHV01 Containing the Cassette for the Expression of the CDV HA Gene in the CHV ORF3 Site.
  • Plasmid pPB213 (see Example 8) was linearized by digestion with HindIII, extracted with a phenol-chloroform mixture, precipitated with absolute ethanol and then taken up in sterile water.
  • MDCK cells forming a well-established cell lawn in a Petri dish (Corning 4.5 cm in diameter) were then transfected with the following mixture: 1 μg of linearized plasmid pPB213+5 μg of CHV viral DNA in 300 μl of MEM medium and 100 μg of LipofectAMINE (Gibco-BRL Cat# 18324-012) diluted in 300 μl of medium (final volume of the mixture=600 μl). These 600 μl were then diluted in 3 ml (final volume) of MEM medium and spread over 3×106 MDCK cells. The mixture was left in contact with the cells for 5 hours, then removed and replaced by 5 ml of culture medium. The cells were then left in culture for 24 hours at +37° C. After 24 hours to 48 hours of culture, 1 ml of culture supernatant was harvested, and several dilutions of this supernatant were used to infect other MDCK cells (cultured in Petri dishes (Corning 4.5 cm in diameter)) so as to obtain isolated plaques, each dish being infected with 1 ml of a dilution of the initial supernatant. After contact for 1 hour at 37° C., the infection medium was removed and replaced by 5 ml of MEM medium containing 1% of agarose, kept supercooled at 42° C. When the agarose had solidified, the dishes were incubated for 48 hours at 37° C. in a CO2 incubator until plaques were seen. The agarose layer was then removed, and a transfer of the viral plaques was carried out onto a sterile nitrocellulose membrane of the same diameter as the Petri dish used for culturing. This membrane was itself transferred onto another nitrocellulose membrane so as to obtain an inverted “copy” of the first transfer. The plaques transferred onto this second copy were then hybridized, according to the standard techniques known to a person skilled in the art, with a 1842-bp NotI-NotI fragment of the CDV HA gene, obtained by digestion of plasmid pPB208 (Example 7.1.), labelled with digoxigenin (DNA Labelling kit, Boehringer Mannheim, CAT # 1175033). After hybridization, washes and contacting with the visualization substrate, the nitrocellulose membrane was placed in contact with an autoradiographic film. The images of positive hybridization on this membrane indicated which plaques were the ones which contained recombinant CHV viruses which had inserted the CDV HA cassette. The plaques corresponding to these positive plaques were cut out under sterile conditions from the first nitrocellulose membrane, placed in an Eppendorf tube containing 0.5 ml of MEM medium and sonicated to release the virions from the membrane. The medium contained in the Eppendorf tube was then diluted in MEM medium, and the dilutions thereby obtained were used to infect further cultures of MDCK cells. A 100% pure recombinant virus containing the HCMV-IE/CDV HA/polyA cassette inserted into the ORF3 site was thereby isolated after 3 cycles of purification, and was called vCHV01. The homology of the recombination was verified by PCR using oligonucleotides situated on each side of the insertion site. The absence of reorganization on the genome of the recombinant virus vCHV01, other than in the recombination region, was verified by the Southern blot technique.
  • Example 15
  • Isolation of Recombinant CHV Viruses Expressing Various Foreign Genes
  • According to the procedure described in Example 14, the construction of different recombinant CHV viruses is carried out using the donor plasmids described in Examples 9 to 13.
  • Example 16
  • Preparation of the Vaccines
  • To prepare a vaccine, the recombinant viruses obtained in Examples 14 and 15 are cultured on MDCK cells. Harvesting of the recombinant virus takes place when the cytopathic effect is complete. The lysed cells and the culture supernatant are harvested. After clarification of the cell lysate to remove cell debris, the viral solution is titrated. The viral solution is then diluted in a stabilizing solution for lyophilization, distributed on the basis of one vaccinal dose (102 CCID50 to 107 CCID50) per vial and lastly lyophilized. The viral solution can then be frozen if necessary.
  • Example 17
  • Vaccination Methods
  • According to the preferred mode of vaccination, the vaccine obtained according to the invention is redissolved or thawed, and then administered via the parenteral or mucosal route, but preferably via the mucosal, in particular the oral and/or nasal, route. The vaccinal dose will preferably be between 102 CCID50 and 107 CCID50. Preferably, the dose for the parenteral route will be between 104 CCID50 and 107 CCID50, and for the oral and/or nasal route, between 102 CCID50 and 105 CCID50. As defined, the vaccine is effective in general after a single administration via the oral and/or nasal route. However, repeated administrations may be necessary.

Claims (32)

1-16. (canceled)
17. A recombinant canine herpes virus (CHV) comprising and expressing at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase.
18. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB.
19. The recombinant CHV of claim 17 wherein the at least one heterologous nucleotide sequence is inserted by simple insertion, or after total or partial deletion of the insertion locus.
20. The recombinant CHV according to claim 17 further comprising a strong eukaryotic promoter; wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter.
21. The recombinant CHV according to claim 20 wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter.
22. The recombinant CHV of claim 21 wherein the CMV immediate-early promoter comprises a murine or human CMV immediate-early promoter.
23. The recombinant CHV according to claim 17 comprising at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter.
24. The recombinant CHV according to claim 23 wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origin.
25. The recombinant CHV according to claim 23 comprising a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter; wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent.
26. The recombinant CHV according to claim 18 further comprising at least one heterologous nucleotide sequence encoding an immunomodulatory polypeptide.
27. The recombinant CHV according to claim 25 wherein the heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of nucleotide sequences encoding cytokines.
28. The recombinant CHV according to claim 17 wherein the heterologous nucleotide sequence comprises an expression cassette comprising from 5′ to 3′, a promoter, two or more coding regions separated in pairs by an internal ribosome entry site (IRES), and a polyadenylation signal.
29. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the canine distemper virus HA antigen.
30. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the canine distemper virus F antigen.
31. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the rabies virus G antigen.
32. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the canine parvovirus VP2 antigen.
33. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 HA antigen.
34. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 F antigen.
35. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspA antigen.
36. The recombinant CHV of claim 18 comprising and expressing at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspB antigen.
37. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence encodes an antigen.
38. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence encodes an immunomodulatory polypeptide.
39. An immunological composition comprising a recombinant CHV; wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence is inserted by simple insertion, or after total or partial deletion of the insertion locus or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase andwherein the recombinant CHV further comprises a strong eukaryotic promoter; wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter and wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter, wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter and wherein the CMV immediate-early promoter comprises a murine or human CMV immediate-early promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origin or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter, wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV further comprises at least one heterologous nucleotide sequence encoding an immunomodulatory polypeptide or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter, wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter; wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent and wherein the heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of nucleotide sequences encoding cytokines or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the heterologous nucleotide sequence comprises an expression cassette comprising from 5′ to 3′, a promoter, two or more coding regions separated in pairs by an internal ribosome entry site (IRES), and a polyadenylation signal orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the rabies virus G antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine parvovirus VP2 antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspA antigen orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspB antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an immunomodulatory polypeptide.
40. A multivalent immunological composition comprising, as a mixture or to be admixed, at least a first recombinant CHV and a second recombinant CHV; wherein the heterologous nucleotide sequence in the first recombinant CHV is different than the heterologous nucleotide sequence in the second recombinant CHV; wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence is inserted by simple insertion, or after total or partial deletion of the insertion locus or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase andwherein the recombinant CHV further comprises a strong eukaryotic promoter; wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter and wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV further comprises a strong eukaryotic promoter, wherein at least one heterologous nucleotide sequence is operably linked to the strong eukaryotic promoter, wherein the strong eukaryotic promoter comprises a CMV immediate-early promoter and wherein the CMV immediate-early promoter comprises a murine or human CMV immediate-early promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the eukaryotic promoters are CMV immediate-early promoters of different animal origin or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter and wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter, wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV further comprises at least one heterologous nucleotide sequence encoding an immunomodulatory polypeptide or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the recombinant CHV comprises at least two heterologous nucleotide sequences inserted into at least one insertion site wherein each heterologous nucleotide sequence is under the control of a different eukaryotic promoter, wherein the recombinant CHV comprises a first heterologous nucleotide sequence operably linked to a first promoter and a second heterologous nucleotide sequence operably linked to a second promoter; wherein, the first promoter comprises a CMV immediate-early promoter, and, the first and second promoters are arranged so that their 5′ ends are adjacent and wherein the heterologous nucleotide sequence comprises a nucleotide sequence selected from the group consisting of nucleotide sequences encoding cytokines or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the heterologous nucleotide sequence comprises an expression cassette comprising from 5′ to 3′, a promoter, two or more coding regions separated in pairs by an internal ribosome entry site (IRES), and a polyadenylation signal orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine distemper virus F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the rabies virus G antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the canine parvovirus VP2 antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 HA antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the parainfluenza virus type 2 F antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspA antigen orwherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase, wherein the at least one heterologous nucleotide sequence encodes an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, Borrelia burgdorferi OspA, and Borrelia burgdorferi OspB and wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence encoding the Borrelia burgdorferi OspB antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an antigen or wherein the recombinant CHV comprises and expresses at least one heterologous nucleotide sequence in at least one insertion site comprising an intergenic region corresponding to genes coding for the large subunit and the small subunit of ribonucleotide reductase and wherein the at least one heterologous nucleotide sequence encodes an immunomodulatory polypeptide.
41. A method for inducing an immunological response in a canine comprising administering to the canine a recombinant CHV as claimed in any one of claims 17 to 36 or 37 or 38.
42. A method for inducing an immunological response in a canine animal comprising administering to the canine an immunological composition as claimed in claim 39.
43. A method for inducing an immunological response in a canine comprising administering to the canine an immunological composition as claimed in claim 40.
44. The method of claim 41 wherein the administering comprises mucosally administering a dose comprising between 102 and 105 CCID50 of the recombinant CHV.
45. The method of claim 42 wherein the administering comprises mucosally administering a dose comprising between 102 and 105 CCID50 of the recombinant CHV.
46. The method of claim 43 wherein the administering comprises mucosally administering a dose comprising between 102 and 105 CCID50 of the recombinant CHV.
47. A method for expressing a polypeptide comprising contacting a suitable cell with a recombinant CHV as claimed in any one of claims 17 to 36 or 37 or 38.
US10/935,494 1996-06-27 2004-09-07 Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2. Abandoned US20060024329A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/935,494 US20060024329A1 (en) 1996-06-27 2004-09-07 Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR96/08242 1996-06-27
FR9608242A FR2750865B1 (en) 1996-06-27 1996-06-27 RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS
PCT/FR1997/001115 WO1997049825A1 (en) 1996-06-27 1997-06-23 Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus
US09/213,053 US6159477A (en) 1996-06-27 1998-12-16 Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus
US59647900A 2000-06-19 2000-06-19
US10/935,494 US20060024329A1 (en) 1996-06-27 2004-09-07 Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2.

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US59647900A Continuation 1996-06-27 2000-06-19

Publications (1)

Publication Number Publication Date
US20060024329A1 true US20060024329A1 (en) 2006-02-02

Family

ID=9493648

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/213,053 Expired - Lifetime US6159477A (en) 1996-06-27 1998-12-16 Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus
US10/935,494 Abandoned US20060024329A1 (en) 1996-06-27 2004-09-07 Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/213,053 Expired - Lifetime US6159477A (en) 1996-06-27 1998-12-16 Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus

Country Status (13)

Country Link
US (2) US6159477A (en)
EP (1) EP0910657B1 (en)
JP (1) JP2000512264A (en)
KR (1) KR20000022213A (en)
AU (1) AU737583B2 (en)
BR (1) BR9710012B1 (en)
CA (1) CA2258735C (en)
CZ (1) CZ297022B6 (en)
FR (1) FR2750865B1 (en)
NZ (1) NZ333546A (en)
PL (2) PL196247B1 (en)
WO (1) WO1997049825A1 (en)
ZA (1) ZA975619B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110302374A (en) * 2019-08-09 2019-10-08 中国农业科学院特产研究所 Canine vaccine and its preparation method and application

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2750865B1 (en) * 1996-06-27 1998-12-04 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS
FR2775601B1 (en) * 1998-03-03 2001-09-21 Merial Sas RECOMBINANT LIVING VACCINES AND ADJUVANTS
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP2158917A1 (en) 2002-09-19 2010-03-03 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services P.ariasi polypeptides, P.perniciosus polypeptides and methods of use
WO2004039958A2 (en) 2002-10-29 2004-05-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
CA2510189A1 (en) * 2002-12-19 2004-07-08 Thomas Gore Trivalent vaccine with maternal antibody transfer via the milk
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
JP4750024B2 (en) 2003-06-20 2011-08-17 プロテイン サイエンシーズ コーポレイション Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, and methods and assays for their production and use
ES2417019T3 (en) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Characterization procedure of infectious bursitis disease virus
NZ549384A (en) 2004-02-19 2008-08-29 Univ Alberta Leptin promoter polymorphisms and uses thereof
EP2198881A1 (en) 2005-04-25 2010-06-23 Merial Limited Nipah virus vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
CN101312742B (en) * 2005-09-16 2012-07-25 梅瑞尔有限公司 Stabilizers for freeze-dried vaccines
EP2186823A1 (en) 2005-11-14 2010-05-19 Merial Limited Gene therapy for renal failure
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
EP2283035B1 (en) 2008-05-08 2015-07-29 Merial Limited Leishmania vaccine using sand fly salivary immunogen
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
EP2701736A1 (en) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
LT2741740T (en) 2011-08-12 2017-08-10 Merial, Inc. Vacuum-assisted preservation of biological products, in particular of vaccines
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
EP2968514A1 (en) 2013-03-12 2016-01-20 Merial, Inc. Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (en) 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
TW202241500A (en) 2015-06-09 2022-11-01 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
CN107922462B (en) 2015-06-23 2022-03-18 勃林格殷格翰动物保健美国公司 Recombinant virus vector containing PRRSV minor protein and its production process and use
WO2017184590A1 (en) 2016-04-18 2017-10-26 The Broad Institute Inc. Improved hla epitope prediction
EP3478066A1 (en) * 2016-06-30 2019-05-08 Next Science IP Holdings Pty Ltd Antimicrobial compositions and methods employing same
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN114790229B (en) * 2022-04-12 2024-07-12 北京慧德易科技有限责任公司 Recombinant protein and preparation method and application thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4213965A (en) * 1979-01-23 1980-07-22 Cornell Research Foundation, Inc. Small-plaque variant canine herpesvirus vaccine
US5356622A (en) * 1991-12-13 1994-10-18 Paravax, Inc. Flea midgut-supernatant vaccines
US5399485A (en) * 1992-01-17 1995-03-21 United States Of America Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by Rochalimaea henselae
US5418137A (en) * 1991-09-26 1995-05-23 Paravax, Inc. Flea membrane binding site proteins as screening tools
US5681724A (en) * 1995-11-16 1997-10-28 Heska Corporation Parasitic helminth macrophage inhibitory factor nucleic acid molecules and uses thereof
US5707817A (en) * 1993-02-05 1998-01-13 Colorado State University Research Foundation Carbohydrate-based vaccine and diagnostic reagent for trichinosis
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US5789194A (en) * 1995-05-23 1998-08-04 Heska Corporation Parasitic helminth venom allergen antigen 5-like genes and proteins
US5795768A (en) * 1991-02-12 1998-08-18 Heska Corporation Filariid nematode cysteine protease proteins, nucleic acid molecules and uses thereof
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US6159477A (en) * 1996-06-27 2000-12-12 Merial Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659349B1 (en) * 1990-03-12 1993-12-24 Rhone Merieux RECOMBINANT HERPIC VIRUSES ESPECIALLY FOR THE PRODUCTION OF VACCINES, THEIR PREPARATION PROCESS, THE PLASMIDS MADE DURING THIS PROCESS AND THE VACCINES OBTAINED.
CA2103788A1 (en) * 1991-02-12 1992-08-13 Robert B. Grieve Reagents and methods for identification of vaccines
US5639876A (en) * 1991-02-12 1997-06-17 Heska Corporation Nucleic acid molecules encoding novel parasitic helminth proteins
AU675214B2 (en) * 1991-11-12 1997-01-30 Colorado State University Research Foundation Protease vaccine against heartworm
WO1996011706A1 (en) * 1994-10-18 1996-04-25 Heska Corporation Use of flea proteases and protease inhibitors to protect animals from flea infestation
US5492695A (en) * 1992-05-14 1996-02-20 Colorado State University Research Foundation Vaccinating cats against Dirofilaria immitis with an L4 homogenate
US5541075A (en) * 1993-02-05 1996-07-30 Heska Corporation Carbohydrate-based vaccine and diagnostic reagent for trichinosis
WO1994017813A1 (en) * 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US5569603A (en) * 1994-03-08 1996-10-29 Heska Corporation Dirofilaria immitis GP29 proteins, nucleic acid molecules and uses thereof
DE69535561T2 (en) * 1994-03-30 2008-06-05 Connaught Technology Corp., Greenville NUCLEOTIDE AND AMINO ACID SEQUENCES gB, gC AND gD OF THE HERPESVIRUS OF THE DOG AND THEIR USES
EP0766693A4 (en) * 1994-05-26 2002-10-30 Heska Corp Novel parasite protease genes and proteins
CA2201482C (en) * 1994-10-07 2011-04-26 Glenn R. Frank Novel ectoparasite saliva proteins and apparatus to collect such proteins
CN1117081A (en) * 1995-03-16 1996-02-21 高云 Triple live vaccine and toxin vaccine for distemper, rabies and pavovirus and its preparing method

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4213965A (en) * 1979-01-23 1980-07-22 Cornell Research Foundation, Inc. Small-plaque variant canine herpesvirus vaccine
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US5795768A (en) * 1991-02-12 1998-08-18 Heska Corporation Filariid nematode cysteine protease proteins, nucleic acid molecules and uses thereof
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5418137A (en) * 1991-09-26 1995-05-23 Paravax, Inc. Flea membrane binding site proteins as screening tools
US5356622A (en) * 1991-12-13 1994-10-18 Paravax, Inc. Flea midgut-supernatant vaccines
US5399485A (en) * 1992-01-17 1995-03-21 United States Of America Methods and compositions for diagnosing cat scratch disease and bacillary angiomatosis caused by Rochalimaea henselae
US5707817A (en) * 1993-02-05 1998-01-13 Colorado State University Research Foundation Carbohydrate-based vaccine and diagnostic reagent for trichinosis
US5789194A (en) * 1995-05-23 1998-08-04 Heska Corporation Parasitic helminth venom allergen antigen 5-like genes and proteins
US5681724A (en) * 1995-11-16 1997-10-28 Heska Corporation Parasitic helminth macrophage inhibitory factor nucleic acid molecules and uses thereof
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
US5804197A (en) * 1996-02-15 1998-09-08 Heska Corporation Recombinant canine herpesviruses
US6159477A (en) * 1996-06-27 2000-12-12 Merial Canine herpesvirus based recombinant live vaccine, in particular against canine distemper, rabies or the parainfluenza 2 virus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110302374A (en) * 2019-08-09 2019-10-08 中国农业科学院特产研究所 Canine vaccine and its preparation method and application

Also Published As

Publication number Publication date
PL196530B1 (en) 2008-01-31
NZ333546A (en) 2001-06-29
JP2000512264A (en) 2000-09-19
BR9710012A (en) 1999-08-10
WO1997049825A1 (en) 1997-12-31
ZA975619B (en) 1998-12-28
EP0910657A1 (en) 1999-04-28
FR2750865A1 (en) 1998-01-16
CA2258735C (en) 2011-06-21
PL196247B1 (en) 2007-12-31
CZ297022B6 (en) 2006-08-16
AU737583B2 (en) 2001-08-23
FR2750865B1 (en) 1998-12-04
PL330879A1 (en) 1999-06-07
CZ428198A3 (en) 1999-04-14
BR9710012B1 (en) 2011-10-18
US6159477A (en) 2000-12-12
KR20000022213A (en) 2000-04-25
AU3447497A (en) 1998-01-14
EP0910657B1 (en) 2013-02-27
CA2258735A1 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
AU737583B2 (en) Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2
US6586412B2 (en) Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
AU739374B2 (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
US6387376B1 (en) Recombinant vaccine containing feline herpes virus type 1 particularly for treating feline infectious peritonitis
AU734085B2 (en) Recombinant live avian vaccine, using as vector the avian infectious laryngotracheitis virus.
US6376473B1 (en) Polynucleotide vaccine formula in particular against bovine respiratory pathology
AU708077B2 (en) Live recombinant avian vaccine using an avian herpesvirus as vector
AU735265B2 (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
CA2223029A1 (en) Canine parvovirus dna vaccines
EP0606452B1 (en) Vector vaccines of recombinant feline herpesvirus
WO1995007987A2 (en) Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor
US7294338B2 (en) Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载